Table 2. Correlations between the changes in BDNF levels between baseline and 12-week follow-up (ng ml−1) and psychopathology at 12-week follow-up.
|
Changes in BDNF |
Changes in pro-BDNF |
|||||
|---|---|---|---|---|---|---|
| All (n=97) | DHA (n=46) | Placebo (n=51) | All (n=97) | DHA (n=46) | Placebo (n=51) | |
| PTSD severity | ||||||
| CAPS total score | −0.177 | −0.284 | −0.053 | −0.164 | −0.219 | −0.086 |
| Depression severity | ||||||
| MADRS total scorea | −0.257* | −0.192 | −0.298* | −0.253* | −0.257 | −0.251 |
| Resilience | ||||||
| CD-RISC total scorea | 0.091 | 0.249 | −0.042 | 0.062 | −0.042 | 0.191 |
Abbreviations: BDNF, brain-derived neurotrophic factor; CAPS, Clinician-Administered PTSD Scale; CD-RISC, Connor–Davidson Resilience Scale; DHA, docosahexaenoic acid; MADRS, Montgomery–Åsberg Depression Rating Scale; PTSD, posttraumatic stress disorder.
a
n=96 in both groups.
*P<0.05.